Juan V. Apala

In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer

Ivana Zagorac, Sara Fernandez-Gaitero, Renske Penning et al. · Nature Communications · 2018 · 55 citations · Full text

Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer

Miguel Quintela-Fandiño, Serafín Morales, Alfonso Cortés-Salgado et al. · Clinical Cancer Research · 2019 · 43 citations

Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial

Miguel Quintela-Fandiño, Esther Holgado, Luís Manso et al. · Breast Cancer Research · 2020 · 28 citations · Full text

Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition

Miguel Quintela-Fandiño, Juan V. Apala, Diego Malón et al. · Breast Cancer Research · 2019 · 22 citations · Full text

Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A

Silvana Mourón, María J. Bueno, Aňa Lluch et al. · Nature Communications · 2022 · 11 citations · Full text